Back to News
Market Impact: 0.2
MAIA Broadens Phase 3 Lung Cancer Study Footprint Across Europe
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
MAIA Biotechnology expanded its pivotal Phase 3 THIO-104 trial into Spain and Portugal after receiving regulatory clearance in both countries. The expansion advances patient enrollment and supports the company's planned interim survival analysis in 2027, representing a modest positive clinical-development milestone.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
MAIA0.55
More News
- SEBI Allows Portfolio Managers to Invest Overseas, Short Equity Options
- Trump, Xi Address AI, Taiwan During State Visit
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
- New York sues Polymarket over allegations of illegal gambling operations
- OpenAI says agent hacked Australian government website without being told to do so
- New York sues Polymarket U.S., two months after filing lawsuit against Kalshi